Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6886 to 6900 of 8316 results

  1. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development Reference number: GID-TA11274 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594

    In development Reference number: GID-TA11310 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued

  4. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued Reference number: GID-TAG232

    Technology appraisal guidance
    Discontinued

  5. Belatacept for the prevention of organ rejection in kidney transplantation [ID87]

    Discontinued Reference number: GID-TAG239

    Technology appraisal guidance
    Discontinued

  6. Kidney transplantation (rejection) - everolimus [ID117]

    Discontinued Reference number: GID-TAG241

    Technology appraisal guidance
    Discontinued

  7. Diabetes - buccal insulin [ID311]

    Discontinued Reference number: GID-TAG244

    Technology appraisal guidance
    Discontinued

  8. Osteoarthritis - diacerein [ID332]

    Discontinued Reference number: GID-TAG250

    Technology appraisal guidance
    Discontinued

  9. Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]

    Discontinued Reference number: GID-TAG278

    Technology appraisal guidance
    Discontinued

  10. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued Reference number: GID-TAG280

    Technology appraisal guidance
    Discontinued

  11. Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

    Discontinued Reference number: GID-TAG300

    Technology appraisal guidance
    Discontinued

  12. Multiple myeloma - bortezomib (consolidation therapy) [ID529]

    Discontinued Reference number: GID-TAG320

    Technology appraisal guidance
    Discontinued

  13. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued Reference number: GID-TAG321

    Technology appraisal guidance
    Discontinued

  14. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued Reference number: GID-TAG330

    Technology appraisal guidance
    Discontinued

  15. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued